Brief: Dr Reddy's Says IDMC Recommends Discontinuation Of TACTI-004 Phase III Trial After Interim Futility Analysis
13/03/2026 13:13
March 13 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS: IDMC RECOMMENDS DISCONTINUATION OF TACTI-004 PHASE III TRIAL AFTER INTERIM FUTILITY ANALYSIS IMMUTEP TO HALT ENROLMENT AND WIND DOWN TACTI-004 PHASE III STUDY Source text: ID:nBSE8hmsTG Further company coverage: REDY.NS ((Reuters.Briefs@thomsonreuters.com;;))